ZA200204096B - An aqueous solution formulation of alpha-interferon. - Google Patents

An aqueous solution formulation of alpha-interferon.

Info

Publication number
ZA200204096B
ZA200204096B ZA200204096A ZA200204096A ZA200204096B ZA 200204096 B ZA200204096 B ZA 200204096B ZA 200204096 A ZA200204096 A ZA 200204096A ZA 200204096 A ZA200204096 A ZA 200204096A ZA 200204096 B ZA200204096 B ZA 200204096B
Authority
ZA
South Africa
Prior art keywords
interferon
alpha
aqueous solution
solution formulation
formulation
Prior art date
Application number
ZA200204096A
Other languages
English (en)
Inventor
Kang Young Cheol
Sang-Heon Lee
Kyuboem Han
Original Assignee
Lg Chem Investment Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chem Investment Ltd filed Critical Lg Chem Investment Ltd
Publication of ZA200204096B publication Critical patent/ZA200204096B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ZA200204096A 1999-11-19 2002-05-23 An aqueous solution formulation of alpha-interferon. ZA200204096B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-1999-0051481A KR100399156B1 (ko) 1999-11-19 1999-11-19 α-인터페론의 용액제형

Publications (1)

Publication Number Publication Date
ZA200204096B true ZA200204096B (en) 2003-02-26

Family

ID=36782398

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200204096A ZA200204096B (en) 1999-11-19 2002-05-23 An aqueous solution formulation of alpha-interferon.

Country Status (23)

Country Link
EP (1) EP1231933B1 (de)
JP (1) JP3893286B2 (de)
KR (1) KR100399156B1 (de)
CN (1) CN1203892C (de)
AR (1) AR026507A1 (de)
AT (1) ATE333891T1 (de)
AU (1) AU777994B2 (de)
BR (1) BR0015699A (de)
CA (1) CA2391889A1 (de)
CY (1) CY1105449T1 (de)
DE (1) DE60029614T2 (de)
DK (1) DK1231933T3 (de)
ES (1) ES2267584T3 (de)
HU (1) HUP0203706A3 (de)
MX (1) MXPA02005105A (de)
PE (1) PE20010903A1 (de)
PL (1) PL356406A1 (de)
PT (1) PT1231933E (de)
RU (1) RU2232595C2 (de)
TR (1) TR200201310T2 (de)
TW (1) TWI223596B (de)
WO (1) WO2001035987A1 (de)
ZA (1) ZA200204096B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US6830744B2 (en) * 2002-05-31 2004-12-14 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
RU2270692C1 (ru) * 2004-11-04 2006-02-27 Валентина Васильевна Малиновская Пролонгированный раствор интерферона
RU2447897C2 (ru) * 2009-03-26 2012-04-20 Сергей Юрьевич Родионов Цитокинсодержащая композиция для лечения вирусных заболеваний
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
RU2012153786A (ru) * 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
KR20150074167A (ko) 2012-10-26 2015-07-01 루핀 리미티드 Ｐｅｇ 인터페론 알파-2ｂ의 안정한 약학 조성물
CN104888196B (zh) * 2015-06-25 2018-07-06 北京三元基因药业股份有限公司 一种稳定的干扰素α多剂量笔注射液
CN105456186A (zh) * 2015-12-24 2016-04-06 杭州嘉伟生物制品有限公司 一种生理平衡液的制备方法
CN114259556B (zh) * 2021-12-24 2024-05-31 科兴生物制药股份有限公司 人干扰素α2b喷雾剂及其制备方法
CN114053397B (zh) * 2022-01-17 2022-12-20 北京三元基因药业股份有限公司 一种稳定的干扰素多剂量注射液及其制备方法
CN115068592A (zh) * 2022-06-27 2022-09-20 长春生物制品研究所有限责任公司 开封后常温稳定的重组人干扰素α1b滴眼液及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution

Also Published As

Publication number Publication date
PE20010903A1 (es) 2001-08-31
AU777994B2 (en) 2004-11-11
DE60029614D1 (de) 2006-09-07
KR20010047312A (ko) 2001-06-15
HUP0203706A3 (en) 2004-12-28
TR200201310T2 (tr) 2002-09-23
RU2002116364A (ru) 2004-01-20
TWI223596B (en) 2004-11-11
JP2003514027A (ja) 2003-04-15
MXPA02005105A (es) 2002-11-07
HUP0203706A2 (hu) 2003-03-28
KR100399156B1 (ko) 2003-09-26
CN1391478A (zh) 2003-01-15
CN1203892C (zh) 2005-06-01
CY1105449T1 (el) 2010-04-28
DK1231933T3 (da) 2006-10-30
BR0015699A (pt) 2002-07-23
EP1231933B1 (de) 2006-07-26
CA2391889A1 (en) 2001-05-25
PT1231933E (pt) 2006-10-31
JP3893286B2 (ja) 2007-03-14
PL356406A1 (en) 2004-06-28
ATE333891T1 (de) 2006-08-15
WO2001035987A1 (en) 2001-05-25
ES2267584T3 (es) 2007-03-16
AU1421601A (en) 2001-05-30
EP1231933A1 (de) 2002-08-21
RU2232595C2 (ru) 2004-07-20
AR026507A1 (es) 2003-02-12
DE60029614T2 (de) 2007-07-12

Similar Documents

Publication Publication Date Title
AU5895700A (en) Aqueous liquid detergent compositions comprising an effervescent system
MXPA01011475A (es) Polimero superabsorbente acuoso y metodos para uso.
BR0013417B1 (pt) composiÇço aquosa.
ZA200204096B (en) An aqueous solution formulation of alpha-interferon.
AU6447100A (en) Method for the evaporation of an aqueous solution containing ammonia
GB2352728B (en) Electrochemical treatment of an aqueous solution
IL147216A0 (en) Arylsulfonamido-substituted hydroxamic acid derivatives
ZA200007748B (en) Aqueous coating composition.
ZA200007747B (en) Aqueous coating composition.
MXPA00012647A (es) Derivados n-sustituidos de acido 5-oxiiminobarbiturico.
ZA200109206B (en) Preparation of substituted piperidin-4-ones.
AU2645699A (en) Aqueous disinfecting solution
HU229988B1 (en) Aqueous lysine solution
AU4756300A (en) Acidic, aqueous, multi-phase cleaning agent
ZA200203078B (en) Ciclesonide-containing aqueous pharmaceutical composition.
GB9929979D0 (en) Hydroxamic acid derivatives
ZA200203311B (en) Pharmaceutical carrier formulation.
EP1142565A4 (de) Wässerige arzneimittel
ZA200001618B (en) A stable aqueous solution of EM 12.
BR0004161B1 (pt) solução de molho ácido.
AU2335600A (en) An aqueous metal working liquid
AU4945500A (en) Aqueous disinfecting solution
ZA200109120B (en) Use of Arylalkanoylpyridazines.
GB0121153D0 (en) Aqueous coating formulation
GB9908900D0 (en) Aqueous paint composition